Hypercholesterolemia and diabetes have a minimal impact on major adverse cardiovascular events (MACE) risk in patients with prostate cancer (PCa) who are treated with androgen deprivation therapy (ADT),...
Following two 12-week studies, the FDA has approved the first ever medication for treating agitation in patients with dementia due to Alzheimer disease.
To better understand the relationship between cardiovascular disease and liver disease in individuals with HIV, researchers examined both traditional risk factors and HIV-specific risk factors of the...
This COVID-19 roundup includes coverage of the FDA’s amendment to its emergency use authorization of the Pfizer-BioNTech booster for pediatric patients, acute myocardial infection deaths rose during omicron...
Among those with statin-intolerance, bempedoic acid, an inhibitor used to decrease elevated levels of low-density lipoprotein cholesterol, was also associated with a lower risk of major adverse...
Did you watch our Multidisciplinary Roundtable on the current challenges and opportunities in digital health innovation for managing patients with heart failure with reduced ejection fraction? Here are some...
The researchers evaluated the effects of two medications used for type 2 diabetes patients on reducing major cardiovascular events in both men and women.
The American Heart Association (AHA) addresses the adverse effect of hypertension in patients receiving anticancer therapies and how the disease should be managed.
The American Heart Association (AHA) released a statement regarding the use of complementary and alternative treatments that are used in the United States for the treatment of heart failure symptoms.
